Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs New York Times Co (NYT) Price & Performance

Ginkgo Bioworks Holdings IncTrade
New York Times CoTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs New York Times Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while New York Times Co trades at $63.73 (market cap $10.28B). The key difference: New York Times Co is far larger — about 20.3× Ginkgo Bioworks Holdings Inc's market cap, and New York Times Co pays a 1.44% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

DNANYT
Market Cap
$505.73M$10.28B
Sector
HealthMedia
52-Week High
$16.14$85.86
52-Week Low
$5.48$54.66
Enterprise Value
$607.68M$9.67B
Dividend Yield
1.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.

The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.

New York Times Co

The New York Times (NYT) trades at $63.93, down 1.34% amid bearish technical signals despite strong Q2 2026 earnings beats. Revenue growth continues with 2025 revenue reaching $2.82B and net income margin expanding to 12.17%. The stock faces technical pressure with RSI at oversold levels near key support at $62-63, while analyst consensus remains cautious with 65% hold ratings.

NYT demonstrates solid fundamental growth with expanding profitability and digital subscription strength, but faces near-term headwinds from slowing subscriber growth and technical weakness. The $77.50 consensus price target suggests 21% upside potential, though execution risks and competitive pressures warrant monitoring for current investors.

Returns comparison

Trailing returns across standard periods

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About New York Times Co

New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.

Read more on NYT